Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Tuesday, 29'th Oct 2024
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
01:47pm, Tuesday, 22'nd Oct 2024
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
Can This Beaten-Down Cathie Wood Stock Bounce Back?
08:00am, Thursday, 17'th Oct 2024
An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
10:15am, Thursday, 10'th Oct 2024
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
Exact Sciences Schedules Third Quarter 2024 Earnings Call
06:00am, Tuesday, 08'th Oct 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 20
FMR LLC Bolsters Stake in Exact Sciences Corp
02:05pm, Monday, 07'th Oct 2024
On September 30, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, significantly increased its investment in Exact Sciences Corp (EXAS, Financial), a leader in cancer diagnostics. The fi
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
09:41am, Friday, 04'th Oct 2024
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
06:00am, Friday, 04'th Oct 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved t
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
02:35am, Monday, 16'th Sep 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
08:21am, Thursday, 12'th Sep 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Wall Street Analysts Believe Exact Sciences (EXAS) Could Rally 34.33%: Here's is How to Trade
10:56am, Monday, 09'th Sep 2024
The mean of analysts' price targets for Exact Sciences (EXAS) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Exact Sciences Corporation (EXAS) at Wells Fargo 2024 Healthcare Conference - Transcript
09:43pm, Wednesday, 04'th Sep 2024
Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 2024 Healthcare Conference September 5, 2024 3:45 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants
Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 30'th Aug 2024
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Exact Sciences to Participate in September Investor Conferences
06:00am, Wednesday, 28'th Aug 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow
